Economic evaluations on cardiovascular preventive interventions in Argentina

References

• The Global Burden of Disease: 2004 Update. World Health Organization, Geneva, Switzerland (2008).
   Google Scholar
• Preventing Chronic Diseases: a Vital Investment. World Health Organization, Geneva, Switzerland (2005).
   Google Scholar
• Mathers CD, Lopez A, Stein C et al. Deaths and Disease Burden by Cause: Global Burden of Disease Estimates for 2001 by World Bank Country Groups. Working Paper Series N° 18 (Second Project on Disease Control Priorities in Developing Countries). World Health Organization; World Bank; and Fogarty International Center, US National Institutes of Health, MD, USA (2005).
   Google Scholar
• Argentina: Indicadores Básicos 2008. Ministerio de Salud, Buenos Aires, Argentina (2008).
   Google Scholar
• Rubinstein A, Colantonio L, Bardach A et al. Estimación de la carga de las enfermedades cardiovasculares atribuible a factores de riesgo modificables en Argentina. Rev. Panam. Salud Publica27(4), 237–245 (2010).
   PubMed Web of Science ®Google Scholar
• Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet366(9496), 1578–1582 (2005).
   PubMed Web of Science ®Google Scholar
• Prevención de las Enfermedades Cardiovasculares: Guía de Bolsillo Para la Estimación y el manejo del Riesgo Cardiovascular. World Health Organization, Geneva, Switzerland (2008).
   Google Scholar
• Gaziano TA, Reddy KS, Paccaud F, Horton S, Chaturvedi V. Cardiovascular disease. In: Disease Control Priorities in Developing Countries. Jamison DT, Breman JG, Measham AR et al. (Eds). Oxford University Press and The World Bank, Washington DC, USA (2006).
   Google Scholar
• Rodgers A, Lawes CM, Gaziano T, Vos T. The growing burden of risk from high blood pressure, cholesterol, and bodyweight. In: Disease Control Priorities in Developing Countries. Jamison DT, Breman JG, Measham AR et al. (Eds). Oxford University Press and The World Bank, Washington DC, USA (2006).
   Google Scholar
• Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular Risk. World Health Organization, Geneva, Switzerland (2007).
   Google Scholar
• Schwappach DL, Boluarte TA, Suhrcke M. The economics of primary prevention of cardiovascular disease – a systematic review of economic evaluations. Cost Eff. Resour. Alloc.5, 5 (2007).
   PubMedGoogle Scholar
• Beaglehole R, Ebrahim S, Reddy S, Voute J, Leeder S. Prevention of chronic diseases: a call to action. Lancet370(9605), 2152–2157 (2007).
   PubMed Web of Science ®Google Scholar
• Gaziano TA, Galea G, Reddy KS. Scaling up interventions for chronic disease prevention: the evidence. Lancet370(9603), 1939–1946 (2007).
   PubMed Web of Science ®Google Scholar
• Augustovski F, Iglesias C, Manca A et al. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics27(11), 919–929 (2009).
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, NY, USA (2005).
   Google Scholar
• Ferrante D, Levy D, Peruga A, Compton C, Romano E. The role of public policies in reducing smoking prevalence and deaths: the Argentina Tobacco Policy Simulation Model. Rev. Panam. Salud Publica21(1), 37–49 (2007).
   PubMed Web of Science ®Google Scholar
• Vazquez-Prokopec GM, Spillmann C, Zaidenberg M, Kitron U, Gurtler RE. Cost–effectiveness of chagas disease vector control strategies in northwestern Argentina. PLoS Negl. Trop. Dis.3(1), e363 (2009).
   PubMedGoogle Scholar
• Wilson LS, Strosberg AM, Barrio K. Cost–effectiveness of Chagas disease interventions in Latin America and the Caribbean: Markov models. Am. J. Trop. Med. Hyg.73(5), 901–910 (2005).
   PubMed Web of Science ®Google Scholar
• Machnicki G. Análisis Costo-Efectividad de Programas Para la Prevención de Enfermedades Coronarias: Revisión de Estrategias Metodológicas. Concurso Asociación de Economía de la Salud de Argentina, Buenos Aires, Argentina (2000).
   Google Scholar
• Grines CL, Marsalese DL, Brodie B et al. Safety and cost–effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J. Am. Coll. Cardiol.31(5), 967–972 (1998).
   PubMed Web of Science ®Google Scholar
• Botto F, Von Schulz Hausmann C, Cúneo J, Herrera V, Ferrante D. Costo-eficacia del uso de ramipril en pacientes de alto riesgo vascular en la Argentina. Rev. Argent. Cardiol.71(1), 16–22 (2003).
   Google Scholar
• Ferrante D. Angioplastía Transluminal Coronaria con Stents Recubiertos. Instituto de Efectividad Clínica y Sanitaria, Documentos de Evaluación de Tecnologías Sanitarias Nro 1, Buenos Aires, Argentina (2003).
   Google Scholar
• Ferrante D, Pichon Riviere A, Augustovski F. Evaluación Económica de Neseritide en la Insuficiencia Cardíaca Descompensada en Argentina. Instituto de Efectividad Clínica y Sanitaria, Documentos de Evaluación de Tecnologías Sanitarias Nro 4, Buenos Aires, Argentina (2005).
   Google Scholar
• Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet370(9604), 2044–2053 (2007).
   PubMed Web of Science ®Google Scholar
• Lim SS, Gaziano TA, Gakidou E et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet370(9604), 2054–2062 (2007).
   PubMed Web of Science ®Google Scholar
• Pichon Riviere A, Augustovski F, Bardach A, Colantonio L, Rubinstein A. Cost–effectiveness of smoking cessation interventions in seven Latin American countries (CS2). In: ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 2nd Latin America Conference. ISPOR, Rio de Janeiro, Brasil (2009).
   Google Scholar
• Rodriguez AE, Maree A, Tarragona S et al. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy totreatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. EuroIntervention5(2), 255–264 (2009).
   PubMed Web of Science ®Google Scholar
• Rubinstein A, Garcia Marti S, Souto A, Ferrante D, Augustovski F. Generalized cost–effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff. Resour. Alloc.7, 10 (2009).
   PubMedGoogle Scholar
• Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. Br. Med. J. (Clin. Res. Ed.)297(6644), 319–328 (1988).
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lauer JA, Hutubessy RC et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet361(9359), 717–725 (2003).
   PubMed Web of Science ®Google Scholar
• Rubinstein A, Colantonio L, Bardach A et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health (In Press).
   Google Scholar
• Bruni JM. Costos Directos de la Atención Médica de las Enfermedades Atribuibles al Consumo de Tabaco en Argentina. Ministerio de Salud y Ambiente de la Nación, Buenos Aires, Argentina (2005).
   Google Scholar
• Lewison G. Beyond SCI citations – new ways to evaluate research. Curr. Sci.89(9), 1524–1530 (2005).
   Web of Science ®Google Scholar
• Rubinstein A, Belizan M, Discacciati V. Are economic evaluations and health technology assessments increasingly demanded in times of rationing health services? The case of the Argentine financial crisis. Int. J. Technol. Assess. Health Care23(2), 169–176 (2007).
   PubMed Web of Science ®Google Scholar
• Rubinstein A, Pichon-Riviere A, Augustovski F. Development and implementation of health technology assessment in Argentina: two steps forward and one step back. Int. J. Technol. Assess. Health Care25(Suppl. 1), 260–269 (2009).
   PubMed Web of Science ®Google Scholar
• Resolución 674/03. Ministerio de Salud, Buenos Aires, Argentina (2003).
   Google Scholar
• Augustovski F, Garay OU, Pichon Riviere A, Rubinstein A, Caporale JE. Economic evaluation guidelines in Latin America: a current snapshot. Expert Rev. Pharmacoecon. Outcomes Res. (2010) (In Press).
   PubMedGoogle Scholar